Dr. Louis Bessette graduated from medical school and completed his residency in Internal Medicine and Rheumatology at Laval University. He trained as a fellow in clinical research at the Multipurpose Arthritis Center, Brigham and Women’s Hospital in Boston and received a master’s degree in epidemiology from the Harvard School of Public Health.
He is a clinical researcher at the Centre de recherche du CHU de Québec-Laval University, assistant professor at Laval University’s School of Medicine. Since 2014, he has been Chief of the Rheumatology Department at the CHU de Québec-Laval University. His main research interests are rheumatoid arthritis and osteoporosis, as well as the quality of life aspects and pharmacoeconomic studies related to these diseases.
Dr. Bessette is the principal investigator of the CATCH study in Quebec City (Canadian Early Arthritis Cohort Study). CATCH is a Canadian multicentre research program that aims at improving the quality of care for people with early inflammatory arthritis. Over 2,000 people are participating in our investigator-initiated research program across Canada (100 subjects in Quebec City). This is the only Canada-wide early arthritis cohort that follows people with new onset inflammatory or rheumatoid arthritis over time to examine the course of their disease and their response to the treatments provided by their healthcare team.
He is co-investigator of the Group for Early Arthritis Research (GEAR). GEAR is a multidisciplinary team of the CHU de Québec-Laval University composed of clinicians and clinical researchers in the field of rheumatology. A model for an early arthritis clinic was put in place in 2014 to give better and earlier access to patients who suffer from rheumatic conditions. Other objectives are to collect clinical data and bio specimens on patients with early arthritis to better understand disease progression and its complications. Collecting these data and bio specimens will provide information on the population in the CHU de Québec-Laval University catchment area, and allow to elaborate strategies to improve patient care and prevent comorbid conditions in patients with early arthritis.
Dr. Bessette is co-director for the CaMOS Quebec City Centre, a large Canadian epidemiologic study in osteoporosis. He is also co-investigator of the Recognizing Osteoporosis and its Consequences in Quebec (ROCQ) Programme, a patient health-management programme aimed at evaluating the diagnostic and treatment care gaps for osteoporosis following a fragility fracture in women aged 50 years and over.
2705, boulevard Laurier
T0-93
Québec, Québec
Canada G1V 4G2
Latest news
Data not available
Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib
Journal ArticleRheumatol Ther, 9 (2), 2022.
Abstract | Links: 
A Bridge Too Far? Real-World Practice Patterns of Early Glucocorticoid Use in the Canadian Early Arthritis Cohort
Journal ArticleACR Open Rheumatol, 4 (1), 2022.
Abstract | Links:
Expectations and educational needs of rheumatologists, rheumatology fellows and patients in the field of precision medicine in Canada, a quantitative cross-sectional and descriptive study
Journal ArticleBMC Rheumatol, 5 (1), 2021.
Abstract | Links:
Prediction of Osteoporotic Fractures in Elderly Individuals: A Derivation and Internal Validation Study Using Healthcare Administrative Data
Journal ArticleJ Bone Miner Res, 36 (12), 2021.
Abstract | Links:
Health Assessment Questionnaire at One Year Predicts All-Cause Mortality in Patients With Early Rheumatoid Arthritis
Journal ArticleArthritis Rheumatol, 73 (2), 2021.
Abstract | Links:
Improvements in Fatigue Lag Behind Disease Remission in Early Rheumatoid Arthritis: Results From the Canadian Early Arthritis Cohort
Journal ArticleArthritis Rheumatol, 73 (1), 2021.
Abstract | Links:
Expression of the myeloid inhibitory receptor CLEC12A correlates with disease activity and cytokines in early rheumatoid arthritis
Journal ArticleSci Rep, 11 (1), 2021.
Abstract | Links:
Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis
Journal ArticleAnn Rheum Dis, 80 (4), 2021.
Abstract | Links:
Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme
Journal ArticleAnn Rheum Dis, 80 (3), 2021.
Abstract | Links:
Treatment Strategies in Early Rheumatoid Arthritis Methotrexate Management: Results From a Prospective Cohort
Journal ArticleArthritis Care Res (Hoboken), 72 (8), 2020.
Abstract | Links:
Recently finished projects
- Platelets and neutrophils: the two culprits mediating pain in inflammatory arthritis, from 2020-01-01 to 2022-12-31